JAZZ analyst estimates

Jazz Pharmaceuticals (JAZZ) analyst ratings, the average price target and its range, and every firm's latest call.

JAZZ analyst ratings and price targets

DateFirmCallTarget
Oct 21, 2026Morgan StanleyJazz Pharmaceuticals price target lowered to $314 from $322 at Morgan Stanley$314.00
Oct 8, 2026RBC CapitalJazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital$296.00
Oct 7, 2026Truist FinancialJazz Pharmaceuticals price target raised to $286 from $281 at Truist$286.00
Sep 24, 2026Goldman SachsJazz Pharmaceuticals resumed with a Buy at Goldman Sachs$337.00
Sep 11, 2026UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS$337.00
Sep 10, 2026BarclaysJazz Pharmaceuticals price target raised to $271 from $270 at Barclays$271.00
Aug 28, 2026RBC CapitalJazz Pharmaceuticals price target raised to $299 from $277 at RBC Capital$299.00
Aug 26, 2026Deutsche BankJazz Pharmaceuticals (JAZZ) PT Raised to $300 at Deutsche Bank$300.00
Aug 26, 2026Canaccord GenuityCanaccord Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)$300.00
Aug 26, 2026NeedhamJazz Pharmaceuticals price target raised to $310 from $292 at Needham$310.00
Aug 26, 2026Morgan StanleyJazz Pharmaceuticals price target raised to $322 from $283 at Morgan Stanley$322.00
Aug 26, 2026Truist FinancialJazz Pharmaceuticals price target raised to $281 from $264 at Truist$281.00
Aug 26, 2026RBC CapitalJazz Pharmaceuticals (JAZZ) PT Raised to $277 at RBC Capital$277.00
Aug 11, 2026Morgan StanleyJazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley$283.00
Aug 4, 2026Deutsche BankJazz Pharmaceuticals price target raised to $287 from $270 at Deutsche Bank$287.00

Updated 2026-11-02 23:11 UTC